The subject of gene patentability is one of the most controversial topics in life sciences. In June 2013, the US Supreme Court reached a unanimous decision in the Association for Molecular Pathology v Myriad Genetics. It stated that companies cannot patent parts of naturally occurring human genes. Managing IP sat down with Fitzpatrick Cella Harper & Scinto attorneys Robert Fischer, John Carlin and Joshua Rothman to discuss the ruling
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Shwetasree Majumder, managing partner of Fidus Law Chambers, discusses fighting gender bias and why her firm is building a strong AI and tech expertise
Hady Khawand, founder of AÏP Genius, discusses creating an AI-powered IP platform, and why, with the law evolving faster than ever, adaptability is key
UK firm Shakespeare Martineau, which secured victory for the Triton shower brand at the Court of Appeal, explains how it navigated a tricky test regarding patent claim scopes